Literature DB >> 1696291

Antibody response of fibrocystic patients to homologous 0-typable and 0-defective isolates of Pseudomonas aeruginosa.

J MacDougall1, M E Hodson, T L Pitt.   

Abstract

Antibody titres to Pseudomonas aeruginosa of sera from 60 adult fibrocystic patients were determined in an enzyme linked immunosorbent assay (ELISA) with whole cells of homologous isolates which had been classified according to 0-antigen state by their reactivity with 0-typing antisera. Patients who were continuously colonised with Ps aeruginosa gave the highest titres: range 1500-64000 (mean 11000) and 500-48000 (mean 9000) with homologous 0-typable and 0-defective isolates, respectively. Lower titres to both varieties of isolates were obtained with recently colonised patients, and non-colonised patients gave titres with reference laboratory strains marginally above those of healthy controls. Serum titres of patients with sequential isolates were strain dependent and did not correlate with the 0-antigen state of the strain. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblot analysis of these sera and strains showed antibody binding primarily to high molecular weight 0-repeating units of lipopolysaccharide. It is concluded that the 0-antigen of the strain of Ps aeruginosa used in the ELISA test does not influence the titre obtained with fibrocystic sera, and it is recommended that serum titres should be assessed with a panel of homologous isolates from patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696291      PMCID: PMC502582          DOI: 10.1136/jcp.43.7.567

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  17 in total

1.  Two simple media for the demonstration of pyocyanin and fluorescin.

Authors:  E O KING; M K WARD; D E RANEY
Journal:  J Lab Clin Med       Date:  1954-08

2.  Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  Arch Dis Child       Date:  1986-11       Impact factor: 3.791

3.  Development of enzyme linked immunosorbent assay (ELISA) to detect antibodies to Pseudomonas aeruginosa cell surface antigens in sera of patients with cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood; M S Losowsky
Journal:  J Clin Pathol       Date:  1986-10       Impact factor: 3.411

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay.

Authors:  S S Pedersen; F Espersen; N Høiby
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

6.  Polyagglutinating and non-typable strains of Pseudomonas aeruginosa in cystic fibrosis.

Authors:  T L Pitt; J MacDougall; A R Penketh; E M Cooke
Journal:  J Med Microbiol       Date:  1986-03       Impact factor: 2.472

7.  Prediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis: a follow-up study.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

8.  Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels.

Authors:  P J Hitchcock; T M Brown
Journal:  J Bacteriol       Date:  1983-04       Impact factor: 3.490

9.  Human IgG antibodies to Pseudomonas aeruginosa core lipopolysaccharide determinants are detected in chronic but not acute pseudomonas infection.

Authors:  M A Jacobson; J D Radolf; L S Young
Journal:  Scand J Infect Dis       Date:  1987

10.  Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis.

Authors:  A E Hollsing; M Granström; M L Vasil; B Wretlind; B Strandvik
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 11.677

View more
  2 in total

1.  Immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharides and exotoxin A in patients with cystic fibrosis or bacteremia.

Authors:  A Brauner; S J Cryz; M Granström; H S Hanson; L Löfstrand; B Strandvik; B Wretlind
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

2.  Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.

Authors:  Joshua T Thaden; Ashley E Keller; Norah J Shire; M Margarita Camara; Linda Otterson; Mike Huband; Caitlin M Guenther; Wei Zhao; Paul Warrener; C Kendall Stover; Vance G Fowler; Antonio DiGiandomenico
Journal:  J Infect Dis       Date:  2015-09-02       Impact factor: 5.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.